Ulahannan Susanna, Smith Peyton, Rios Jennifer, Chawla Lakhmir
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, OK 73104, USA.
ExThera Medical, Martinez, CA 94553, USA.
Oncotarget. 2025 Jul 23;16:582-586. doi: 10.18632/oncotarget.28756.
Despite significant strides in the management of metastatic solid tumors over the past few decades, metastatic disease remains a major clinical challenge, often leading to unfavorable patient outcomes. Circulating tumor cells (CTCs), which shed from the primary tumor, have the potential to disseminate and establish distant metastases, contributing to disease progression and reduced survival rates. Removal of CTCs via extracorporeal blood filtration could have significant therapeutic implications.
A 51-year-old woman was diagnosed with metastatic poorly differentiated adenocarcinoma after presenting with severe abdominal pain. She deferred conventional chemotherapy options and elected treatment with CTC removal using an extracorporeal blood filter. After 9-12 filtration sessions of treatment over 12 months, she reported significant clinical improvement and staging scans demonstrated stable disease without evidence of new metastases.
Therapeutic modalities that explore CTC removal via blood filtration may potentially have promising clinical benefits. More prospective studies are required to determine the utility of this therapeutic strategy in patients with metastatic solid tumors. Our patient demonstrated significant clinical improvement with scans demonstrating stable disease.
尽管在过去几十年里转移性实体瘤的治疗取得了重大进展,但转移性疾病仍然是一个主要的临床挑战,常常导致患者预后不佳。从原发肿瘤脱落的循环肿瘤细胞(CTC)有可能扩散并形成远处转移,导致疾病进展和生存率降低。通过体外血液过滤去除CTC可能具有重大的治疗意义。
一名51岁女性因严重腹痛就诊,被诊断为转移性低分化腺癌。她推迟了传统化疗方案,选择使用体外血液过滤器进行CTC清除治疗。在12个月内进行了9 - 12次过滤治疗后,她报告临床症状有显著改善,分期扫描显示疾病稳定,无新转移灶迹象。
通过血液过滤探索去除CTC的治疗方式可能具有有前景的临床益处。需要更多前瞻性研究来确定这种治疗策略在转移性实体瘤患者中的效用。我们的患者经扫描显示疾病稳定,临床症状有显著改善。